Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ENZON PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for ENZON PHARMACEUTICALS, INC.

ENZN

ENZON PHARMACEUTICALS, INC.

About ENZON PHARMACEUTICALS, INC.

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company positioned as an acquisition vehicle, focusing on acquiring businesses or assets to utilize its net operating loss carryforwards (NOLs). It primarily generates revenue through licensing, royalties, and milestone payments from proprietary drug technologies, with limited or no current operations. The company emphasizes strategic acquisitions, royalty streams, and tax assets to enhance shareholder value.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ENZON PHARMACEUTICALS, INC.

1
1
ENZON PHARMACEUTICALS, INC. Viskase Holdings Reports $6.7M Net Loss, Completes Merger with Viskase Companies

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
ENZON PHARMACEUTICALS, INC. Enzon Pharmaceuticals Reports Revenue Decline and Plans Merger with Viskase Companies

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ENZON PHARMACEUTICALS, INC. Enzon Pharmaceuticals Reports Decline in Revenue and Increased Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ENZON PHARMACEUTICALS, INC. Enzon Pharmaceuticals Reports Decline in Revenue and Increased Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ENZON PHARMACEUTICALS, INC. Enzon Pharmaceuticals Reports $524,000 Net Loss in Q1 2025, Revenue Remains Zero

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ENZON PHARMACEUTICALS, INC. Enzon Pharmaceuticals Reports Revenue Growth and Strategic Shift for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ENZON PHARMACEUTICALS, INC. Enzon Pharmaceuticals Reports Modest Revenue Growth, Operating Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments